| Dapagliflozin for non-alcoholic fatty liver disease: a systematic review and meta-analysis. | 2022 | Diabetes Research and Clinical Practice |
| Impacts of sodium/glucose cotransporter-2 inhibitors on circulating uric acid concentrations: a systematic review and meta-analysis. | 2022 | Journal of Diabetes Research |
| Sodium-glucose cotransporter-2 inhibitors and risk of diabetic ketoacidosis among adults with type 2 diabetes: a systematic review and meta-analysis. | 2022 | Canadian Journal of Diabetes |
| Treatments for chronic kidney disease: a systematic literature review of randomized controlled trials. | 2022 | Advances in Therapy |
| Comparative efficacy of five SGLT2i on cardiorenal events: a network meta-analysis based on ten CVOTs. | 2022 | American Journal of Cardiovascular Drugs |
| Association of SGLT2 inhibitors with risk of atrial fibrillation and stroke in patients with and without type 2 diabetes: a systemic review and meta-analysis of randomized controlled trials. | 2022 | Journal of Cardiovascular Pharmacology |
| Sodium-glucose cotransporter 2 inhibitors in patients with heart failure: a systematic review and meta-analysis of randomized trials. | 2022 | European Heart Journal: Quality of Care and Clinical Outcomes |
| Effects of dapagliflozin in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials. | 2022 | Clinics and Research in Hepatology and Gastroenterology |
| Effects of SGLT2 inhibitors on haematocrit and haemoglobin levels and the associated cardiorenal benefits in T2DM patients: a meta-analysis. | 2022 | Journal of Cellular and Molecular Medicine |
| The effectiveness of SGLT2 inhibitor in the incidence of atrial fibrillation/atrial flutter in patients with type 2 diabetes mellitus/ heart failure: a systematic review and meta-analysis. | 2022 | Journal of Thoracic Disease |
| Comparative efficacy of sodium-glucose cotransporter-2 inhibitors (SGLT2i) for cardiovascular outcomes in type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials. | 2021 | Heart Failure Reviews |
| High-dose sodium-glucose co-transporter-2 inhibitors are superior in type 2 diabetes: a meta-analysis of randomized clinical trials. | 2021 | Diabetes, Obesity & Metabolism |
| Association of SGLT2 inhibitors with arrhythmias and sudden cardiac death in patients with type 2 diabetes or heart failure: a meta-analysis of 34 randomized controlled trials. | 2021 | Heart Rhythm |
| Comparative efficacy of 5 sodium glucose cotransporter 2 inhibitor and 7 glucagon-like peptide 1 receptor agonists interventions on cardiorenal outcomes in type 2 diabetes patients. | 2021 | Medicine |
| Microvascular benefits of new antidiabetic agents: a systematic review and network meta-analysis of kidney outcomes. | 2021 | Journal of Clinical Endocrinology & Metabolism |
| Relative efficacy of sacubitril-valsartan, vericiguat, and SGLT2 inhibitors in heart failure with reduced ejection fraction: a systematic review and network meta-analysis. | 2021 | Cardiovascular Drugs and Therapy |
| Effect of SGLT-2 inhibitors on non-alcoholic fatty liver disease among patients with type 2 diabetes mellitus: systematic review with meta-analysis and trial sequential analysis of randomized clinical trials. | 2021 | Oman Medical Journal |
| Effects and safety of SGLT2 inhibitors compared to placebo in patients with heart failure: a systematic review and meta-analysis. | 2021 | IJC Heart & Vasculature |
| Comparative effectiveness of glucose-lowering drugs for type 2 diabetes: a systematic review and network meta-analysis. | 2020 | Annals of Internal Medicine |
| Peripheral artery disease and amputations with sodium-glucose co-transporter-2 (SGLT-2) inhibitors: a meta-analysis of randomized controlled trials. | 2019 | Diabetes Research and Clinical Practice |
